


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Henry Ford Macomb Hospital</p> <p>2. Radiation Safety Office, K-3 2799 W Grand Blvd. Detroit, MI 48202</p>	<p>In accordance with letter dated January 19, 2024,</p> <p>3. License No.: 21-11850-01 is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: April 30, 2025</p>
		<p>5. Docket No.: 030-02106 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 31.11</p> <p>E. Yttrium-90 permitted by 10 CFR 35.1000</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Prepackaged Kits</p> <p>E. Microspheres</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1 curie total</p> <p>D. 50 millicuries total</p> <p>E. Not to exceed 540 millicuries per vial and 2 curies total</p>
		<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p> <p>D. For use in in-vitro studies.</p> <p>E. For use in the BWXT Medical Ltd. TheraSphere permanent brachytherapy delivery system.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-11850-01

Docket or Reference No.:
030-02106

Amendment No. 79

CONDITIONS

10. A. Licensed material listed in Item Nos. 6.A. through 6.E. may be used at the licensee's facilities located at 15855 Nineteen Mile Road, Clinton Township, Michigan.
- B. Licensed material listed in Item No. 6.B. may be used at the licensee's facilities located at 133 S Main St., Ste. D, Mt. Clemens, Michigan.
11. A. The Radiation Safety Officer (RSO) for this license is Alan M. Jackson, M.S., CHP.
- B. The Associate Radiation Safety Officer (ARSO) for this license is Mayur V. Vaya, CNMT, for 10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300, and 10 CFR 35.1000 (limited to Y-90 TheraSpheres).
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D., D.O., etc.)

Material and Use

Ishani Dalal, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.1000 (limited to Y-90 TheraSpheres)
Xiaoni Hong, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.1000 (limited to Y-90 TheraSpheres)
John Kalabat, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.1000 (limited to Y-90 TheraSpheres)
David Sean Lin, M.D.	10 CFR 35.100, 35.200 and 35.300
Kevin M. O'Brien, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.1000 (limited to Y-90 TheraSpheres)
Vijay Patel, M.D.	10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-11850-01

Docket or Reference No.:
030-02106

Amendment No. 79

Authorized User (M.D., D.O., etc.)


Shehbaz Hasan Shaikh, M.D.

Firas Yazigi, M.D.

Material and Use

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries) and 10 CFR 35.1000 (limited to Y-90 Thera Spheres)

10 CFR 35.200

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated May 21, 2015 (ML15212A665)
 - B. Letter dated October 9, 2014 (ML14283A596)
 - C. Letter dated May 21, 2015 (ML15146A424)
 - D. Letter dated September 14, 2015 (ML15296A523)
 - E. Letter dated June 12, 2017 (ML17164A222)
 - F. Letter dated April 2, 2020 (ML20125A073)
- 


**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-11850-01

Docket or Reference No.:
030-02106

Amendment No. 79

- G. Letter dated July 7, 2021, excluding references: to SIR-Spheres; 10 CFR 35.500 use for Dr. Kevin O'Brien; to authorize for Y-90 TheraSpheres use: Ishani Dalal, M.D., Xiaoni Hong, M.D., John Kalabat, M.D. and Kevin M. O'Brien, M.D.; and to self- updating of TheraSphere procedures as needed (ML21197A061)
- H. Letter dated March 31, 2022 (ML22094A148)
- I. Letter dated May 1, 2023 (ML23124A272)
- J. Letter dated June 29, 2023 (ML23180A235)
- K. Letter dated January 19, 2024 (ML24024A088)
- L. Letter dated April 24, 2024 (ML24116A031)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: June 20, 2024

By: _____

Colleen Carol Casey
Region 3